TRADING ON THE OTC - SYMBOL : PGUZ
OUR PRODUCTS : MEDICAL BACKGROUND & RESEARCH DATA : MANAGEMENT : INVESTORS/NEWS : LINKS : CONTACT US

 

 

 

 

Home Page  |  

 

Daniel P. Kesonen , Chairman & CEO
Pegasus Pharmaceuticals Inc. & Heartview LLC

Mr. Kesonen is also the current Managing Director of RLK Investment Group, an international investment and venture capital corporation, with offices in Florida and Zurich, Switzerland . He is also the Chairman & CEO of Nevtah Capital Management Corp., an oilsands technology company Trading on the OTC market (Symbol: NTAH). Mr. Kesonen is President of Wyn Developments Inc., a resource company trading on the Toronto Venture Exchange (Symbol: WL.V). In the past, he has served as President of PLC Systems Inc., a medical laser company trading on the AMEX Exchange.

In the investment industry, Mr. Kesonen has been Vice President of several investment companies including Shearson Lehman Brothers, E.F. Hutton and A.G. Edwards & Sons. He has an extensive network of contacts in Europe , United States and Canada within the institutional investment community. His background in the investment banking industry will assist Pegasus Pharmaceuticals in the course of developing the Company's strategic platform, its infrastructure, its financial resources and its marketing strategies.

Anatoly S. Soula, Ph. D.,
Vice-President & Director, Heartview LLC,
Partner, Cardio Vision Partnership

Mr. Soula is currently the Vice President, Research & Development of the Cardio Vision Partnership with Dr. Grishin and is largely responsible for the development of the Cardio Visor System, the Russian version of the diagnostic system from which the Pegasus/HeartPortraitT 6S System was developed. He headed up the team conducting clinical trials and received approval from the Russian Ministry of Health, subsequently receiving approval of the device along with the appropriate patents in Russia and the required Europatents for Europe .

He has assisted in the development of the Company's HeartPortrait 6S System for the American market with the application for the appropriate patents and the inception of clinical trials in the United States . Mr. Soula was the M & D Manager of Cybernetic Vision Co., ( Germany ) which designed and marketed a PC supplement for the early detection of heart disease as a consumer device for the European market. He was also the Chief Developer and the Research & Development's Deputy Director of the Information Technology Institute of Moscow and served as Chief Developer, Research & Development Vice President for Financial-Industrial Corp. for the development of diagnostic systems of the MIG-29 fighter plane gas/turbine engines.

Mr. Soula's educational accomplishments include an MS Degree in Radiophysics from the Moscow Power Institute, a Candidate of Sciences Degree (an equivalent of a Ph.D.) from the Institute of Aviation Technics and was named Senior Researcher from the Highest Attestation Commission of the USSR. He is a Corresponding Member of the International Academy of Informatics, Patents and Publications. He is the holder of many Europatents, as well as Russian patents for diagnostic devices. Mr. Soula has been published in more than 80 technical journals, Ministries of Defense, Aviation, Metallurgy and the Academy of Sciences . He will continue to provide the Company with his technical expertise in the development of diagnostic devices as the Pegasus/Heartview HeartPortraitT 6S System continues its enhancement, as well as other diagnostic products that will be brought to market in the coming years.

Dr. Thomas W. Roberts, B.S., D.D.S.,
Consultant
Pegasus Pharmaceuticals Inc.

Dr. Thomas is an accomplished practitioner and researcher in the field of dentistry and currently has a private practice in general and implant dentistry in West Palm Beach, Florida . He has been involved in dentistry research for over 24 years as part of a medical team for projects such as Phase-Contrast Microscope Evaluation of Healthy & Failing Human Dental Implants, Clinical & Microbiological Evaluation of Hydroxyapatite, Assessment of Peri-Implant Sulcular Temperatures in Human with ABIODENT PerioTemp Probe Systems and Prevention of Chlorhexidine-Related Tooth Stain. He presented a scientific presentation at the 1991 International Association for Dental Research 69 th General Session in Acapulco, Mexico with "Early Microflora of Hydroxyapatite-Coated & Pure Titanium Human Dental Implants." Dr. Thomas also presented "Implementation of Periodontal diagnosis & Therapy in General Dental Practice in a multi-city presentation, as well as presenting "The Evaluation of Peri-Implant Sucular Temperature" for the American Association for Dental Research in 1992 and presented "Survival Analysis of Long Arm Ramus Frame Dental Implants for the AADR in 1996.

Dr. Thomas was part of a nine year surgical analysis team focusing on Ramus Frame Dental Implants, the subject of many articles published in such professional journals such as the Journal of Dental Research, Journal of Prosthetic Dentistry, Clinical Oral Implants Research (a manuscript submitted for publication), Journal of Oral Implantology and the Journal of Clinical Periodontology. He has been awarded the Associate Fellow of the American Academy of Implant Dentistry and is Board Qualified for the American Board of Implantology and is a member of the American Academy of Implant Dentistry and the American & International Associations for Dental Research. His extensive background in medical research will greatly assist the Company as it develops and enhances its medical diagnosis products in the international marketplace.

Olof Hildebrand,
Director,
Pegasus Pharmaceuticals Inc.

Mr. Hildebrand obtained his Bachelor of Law Degree at the Uppsala University in Sweden . He served as a Solicitor in Stockholm for several years, including general counsel for the Sandvik Steel Works. He provided general counsel and served as the Vice President-Administration for the AGA AB, an international group of companies based in Sweden . He presently works as a consultant with a focus on administration and organization and is fluent in Swedish, English, French and German. Mr. Hildebrand provides his corporate talents to Pegasus on the Board of Directors.

 


Copyright © 2006, Pegasus Pharmaceuticals Inc.